... HAEGARDA is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC. ... *Advocates are not healthcare providers or medical experts and are compensated for their participation. Powered by Madgex Job Board Software "MHA is delighted to receive this generous LEAD grant from CSL Behring. It is this kind of dedication that CSL Behring provides back to the bleeding disorder community that allows chapters like ours to provide excellent care and service to our community," Kristian Prill, Executive Director said. During the current funding cycle, the community-based grant was awarded to New England Hemophilia Association (NEHA), Neuropathy Action Foundation (NAF), Bleeding Disorders Association of "Through our LEAD Grant program, we have awarded grants to a number of patient advocacy organizations totalling almost The deadline for submitting proposals for the next LEAD Grant cycle is CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. ""The IDF thanks CSL Behring for the LEAD grant and for letting the voices of those with primary immunodeficiencies be heard," Lawrence A. LaMotte, Director Public Policy, IDF, said. "The LEAD grant will enable us to pick up where we left off in 2010 and provide funding to continue HFM Maryland Days and educate future advocates. "The funding being provided will allow us to increase education and advocacy for bleeding disorders and healthcare reform at a critical time in the process. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. We look forward to working with CSL Behring to serve our community," said Kevin R. Sorge, Executive Director, NEHA. CSL Behring is a subsidiary of Issuers of news releases and not csrwire are solely responsible for the accuracy of the content

Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support "The Association is passionate about making a better life for all HAE patients and is grateful for the opportunity to advocate for HAE research on a federal level," said Janet F. Long, Executive Vice President of the US HAEA.CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. "NEHA is grateful to receive a LEAD grant from CSL Behring in support of our Advocacy program. "The Foundation is thrilled to be awarded a CSL Behring LEAD Grant. CSL Behring develops and delivers … Sr. Promoting the needs of the bleeding disorders community in our six-state area presents many challenges. CSL Behring has awarded $500,000 in grants to patient organizations since the LEAD program was established in 2008KING OF PRUSSIA, Pa., Jan. 20 /CSRwire/ - /PRNewswire/ - "CSL Behring is pleased to recognize and support these organizations, all of which play a vital role in expanding patient access to information and healthcare," said Dennis Jackman, Senior Vice President, Public Affairs, CSL Behring. CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients Published: Mar 30, 2017 KING OF PRUSSIA, Pa. , March 29, 2017 /PRNewswire/ -- Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD) grants to support advocacy work of rare disease patient groups. Careers. The below links are where you can learn more about organizational advocates doing work for and on behalf of the vast patient communities served by plasma-derived therapies. Thank you CSL Behring for bringing us one step closer to passage of the Hemophilia Standards of Care Act!" A program that provides patients with access to a collection of financial and educational resources. We are a division of CSL Behring, a plasma protein biotherapies company. Learn more. All rights reserved. "We hope these grants will help improve the lives of people with bleeding disorders, immune deficiencies and hereditary angioedema. CSL Behring is part of the CSL Group, which has more than 25,000 employees and does business in 60+ countries. This grant will help our ultimate goal to make all our members better self-advocates," Kristin Marema, MHA Board Member, said.